13F Holdings
中文EN

SOLV Solventum Corp

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1964738 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.8%
TTM net income YoY-89.8%
TTM EPS YoY-89.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin54.8%
Operating margin5.6%
Net margin1.9%
FCF margin0.0%
EBITDA margin9.6%

Returns

ROE3.2%
ROA1.1%
ROIC (approx.)4.7%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets66.1%
Debt / equity1.05x
Current ratio1.03x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.99x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue3.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$8.32B$8.25B$8.20B$8.13B
Gross profit$4.45B$4.59B$4.69B$4.70B
R&D expense$739.00M$775.00M$758.00M$767.00M
SG&A expense$3.08B$2.78B$2.30B$2.23B
Operating income$2.18B$1.04B$1.69B$1.69B
Pretax income$1.71B$605.00M$1.67B$1.69B
Income tax$157.00M$127.00M$321.00M$349.00M
Net income$1.56B$479.00M$1.35B$1.34B
EBITDA$2.67B$1.59B$2.25B$2.27B
EPS (basic)8.942.777.797.78
EPS (diluted)8.882.767.797.78
Weighted avg. shares (diluted)175.30M173.70M172.70M172.70M
Balance sheet
Cash & equivalents$878.00M$762.00M$194.00M$61.00M
Receivables$1.03B$1.04B$1.31B—
Inventory$1.07B$965.00M$857.00M—
Current assets$3.86B$3.25B$2.52B—
PP&E, net$1.33B$1.62B$1.46B—
Goodwill$5.70B$6.38B$6.54B$6.43B
Intangibles$2.59B$2.54B$2.90B—
Total assets$14.29B$14.46B$13.94B—
Current liabilities$3.14B$2.70B$1.73B—
Short-term debt$0$200.00M$0—
Long-term debt$5.04B$7.81B$0—
Total debt$5.04B$8.01B$0—
Total liabilities$9.24B$11.50B$2.28B—
Shareholders' equity$5.05B$2.96B$11.67B$11.74B
Net debt$4.16B$7.25B-$194.00M—
Shares outstanding173.49M172.79M0—
Cash flow statement
Operating cash flow$369.00M$1.19B$1.92B$1.68B
Capital expenditure$379.00M$380.00M$290.00M$251.00M
Free cash flow-$10.00M$805.00M$1.62B$1.43B
Investing cash flow$2.80B-$380.00M-$230.00M-$253.00M
Financing cash flow-$3.06B-$240.00M-$1.55B-$1.46B
Depreciation & amortization$489.00M$555.00M$561.00M$578.00M
Stock-based compensation$161.00M$112.00M$39.00M$37.00M

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.